LVW Advisors LLC Buys 363 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

LVW Advisors LLC boosted its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 11.7% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,468 shares of the medical research company’s stock after acquiring an additional 363 shares during the quarter. LVW Advisors LLC’s holdings in Charles River Laboratories International were worth $683,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in CRL. FIL Ltd lifted its position in Charles River Laboratories International by 23.2% in the 4th quarter. FIL Ltd now owns 662,650 shares of the medical research company’s stock valued at $156,650,000 after acquiring an additional 125,000 shares in the last quarter. Polen Capital Management LLC lifted its position in Charles River Laboratories International by 26.4% in the 4th quarter. Polen Capital Management LLC now owns 6,328 shares of the medical research company’s stock valued at $1,496,000 after acquiring an additional 1,323 shares in the last quarter. Wahed Invest LLC lifted its position in Charles River Laboratories International by 9.5% during the 4th quarter. Wahed Invest LLC now owns 861 shares of the medical research company’s stock worth $204,000 after buying an additional 75 shares in the last quarter. Vanguard Group Inc. lifted its position in Charles River Laboratories International by 0.4% during the 4th quarter. Vanguard Group Inc. now owns 5,980,306 shares of the medical research company’s stock worth $1,413,744,000 after buying an additional 26,446 shares in the last quarter. Finally, PNC Financial Services Group Inc. lifted its position in Charles River Laboratories International by 5.6% during the 4th quarter. PNC Financial Services Group Inc. now owns 11,490 shares of the medical research company’s stock worth $2,716,000 after buying an additional 606 shares in the last quarter. 98.91% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. UBS Group cut their price target on shares of Charles River Laboratories International from $290.00 to $240.00 and set a “buy” rating on the stock in a research report on Thursday, August 8th. Baird R W cut shares of Charles River Laboratories International from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 8th. Argus reissued a “hold” rating on shares of Charles River Laboratories International in a research report on Friday, June 28th. TD Cowen cut their price target on shares of Charles River Laboratories International from $228.00 to $203.00 and set a “hold” rating on the stock in a research report on Monday, August 12th. Finally, Citigroup lowered shares of Charles River Laboratories International from a “neutral” rating to a “sell” rating and lowered their price objective for the stock from $215.00 to $175.00 in a research note on Tuesday, October 1st. One equities research analyst has rated the stock with a sell rating, eleven have given a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $217.33.

Charles River Laboratories International Stock Up 0.8 %

Charles River Laboratories International stock opened at $192.97 on Friday. The stock has a market cap of $9.96 billion, a P/E ratio of 23.11, a P/E/G ratio of 5.11 and a beta of 1.36. The company has a quick ratio of 1.21, a current ratio of 1.58 and a debt-to-equity ratio of 0.65. Charles River Laboratories International, Inc. has a twelve month low of $161.65 and a twelve month high of $275.00. The company’s 50-day moving average price is $198.80 and its two-hundred day moving average price is $216.62.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings results on Wednesday, August 7th. The medical research company reported $2.80 earnings per share for the quarter, beating the consensus estimate of $2.39 by $0.41. Charles River Laboratories International had a net margin of 10.83% and a return on equity of 14.96%. The firm had revenue of $1.03 billion for the quarter, compared to analysts’ expectations of $1.03 billion. As a group, analysts expect that Charles River Laboratories International, Inc. will post 10.01 EPS for the current year.

Charles River Laboratories International declared that its Board of Directors has approved a stock buyback program on Wednesday, August 7th that allows the company to buyback $1.00 billion in outstanding shares. This buyback authorization allows the medical research company to purchase up to 9.6% of its shares through open market purchases. Shares buyback programs are typically a sign that the company’s management believes its shares are undervalued.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).